The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

Jan. 27, 2021
Applicant:

Tyrnovo Ltd., Tel Aviv, IL;

Inventors:

Hadas Reuveni, Har Adar, IL;

Izhak Haviv, Rosh Pina, IL;

Lana Kupershmidt, Kiryat Bialik, IL;

Assignee:

TYRNOVO LTD., Tel Aviv, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/165 (2006.01); A61K 31/436 (2006.01); A61K 31/4375 (2006.01); A61K 31/505 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/165 (2013.01); A61K 31/436 (2013.01); A61K 31/4375 (2013.01); A61K 31/505 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 39/39558 (2013.01); C07K 16/2863 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01);
Abstract

Provided is a treatment of cancer using a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), as well with other agents. The combination can be used to treat a tumor that has developed resistance to an EGFR inhibitor, EGFR antibody, mTOR inhibitor, MEK inhibitor, mutated B-Raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence following cease of treatment with any of said inhibitors or agents or a combination thereof. The subject matter further provides a treatment of cancer using combination therapy comprising a dual modulator of IRS and Stat3, in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.


Find Patent Forward Citations

Loading…